With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a ...

Researchers uncovered how cells coordinate genetic compensation when faulty mRNA is degraded. Small RNA fragments act as sequence “addresses” that recruit ILF3 to activate related backup genes.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...

America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

In a major blow to vaccine development, the FDA said it will not review Moderna’s application for the first mRNA-based flu shot.

The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...